Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis

A method for therapy and/or prophylaxis of:

• (i) a bacterial infection caused by:
• a bacterium that expresses a bacterial glutaminyl cyclase (bacQC), wherein the bacQC is a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
• 1, SEQ ID NO:
• 2, SEQ ID NO:
• 3, and an amino acid sequence having a sequence identity of 80% or more to any one of SEQ ID NO:
• 1, SEQ ID NO:
• 2 and SEQ ID NO:
• 3,
• a bacterium selected from the group consisting of Porphyromonas gingivalis, Prevotella intermedia and Tannerella forsythia, or
• a bacterium selected from the group consisting of Porphyromonas gingivalis, Prevotella intermedia and Tannerella forsythia, wherein the growth of said bacterium within a biofilm is selectively inhibited;
• or
• (ii) an acute, chronic or recurrent periodontal disease;
• wherein the method comprises administration of a therapeutically effective amount of a compound according to the following Formula I:
• or an enantiomer, a diastereoisomer, a hydrate, a solvate, a crystal form, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:
• Ar is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
• wherein L is selected from the group consisting of single bond, —CR5(R6)—, —CR5(R6)—CR7(R8)— and —C(R5)═C(R6)—;
• wherein R1, R2, R5, R6, R7 and R8 are the same or different from each other and are independently selected from the group consisting of H, F, Cl, Br, I, OH, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroalkyl and optionally substituted heteroaryl;
• R3 and R4 are the same or different from each other and are independently selected from the group consisting of H, F, Cl, Br, I, OH, optionally substituted alkyl, and optionally substituted heteroalkyl;
• wherein within each pair of groups R1/R2, R3/R4, R5/R6 and R7/R8, the two groups can be optionally joined together to form a carbocyclic or a heterocyclic ring, or can optionally represent ═O;
• or a pharmaceutical composition comprising said compound, or an enantiomer, a diastereoisomer, a hydrate, a solvate, a crystal form, a tautomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient;
• to a subject in need thereof.